September 12, 2024 — The obesity buzz of the day at EASD annual meeting is clearly amycretin. Amycretin is a new oral medication under study for obesity that activates both GLP-1 and amylin receptors. The excitement came because this is the first public presentation of clinical data on amycretin. This news is impressive on two counts. First, the dosage […]
September 7, 2024 — Recently, Novo Nordisk CEO Lars Fruergaard Jørgensen did a rare interview with NBC News to talk about the high price of obesity medicines that are proving to be so important for so many people. It seemed like a dress rehearsal for his coming appearance at a Senate hearing on the subject. He brought up the […]
![Tusch [Fanfare]](https://conscienhealth.org/wp-content/uploads/2024/08/Tusch-Fanfare-501x334.jpg)
August 17, 2024 — Never is a long time and repeatedly telling people NO can be a futile exercise. Thus, doctors are landing somewhere between no and maybe on the use of compounded obesity medicines. Some are seeing a rationale for for using them while others remain resolute in opposition to them. Shauna Levy is an obesity medicine physician […]
August 16, 2024 — Is the price for health equity in obesity care too high? Or do policy makers simply not care to make it a priority? Writing in the Washington Post, Reverend Al Sharpton tells us that advances in obesity care bring an appalling failure of health equity into plain view: “Despite rates of obesity among people of […]
June 29, 2024 — The revolution in obesity treatment has brought surprising new discoveries along with a lot of unsettling change. Among those discoveries is that food noise is a big part of living with obesity for many people. The noise of food cues all around us sets up intrusive thoughts. It can come to dominate the lived experience […]
June 26, 2024 — One of the four dimensions that sum to a terrible problem of inadequate scale in obesity care is cost. Right now, the list prices for obesity medicines like semaglutide and tirzepatide in the U.S. put them out of reach for all but the wealthy and the well-insured. So will it help that a generic GLP-1 agonist – […]
June 25, 2024 — It’s over. The 84th Scientific Sessions of the American Diabetes Association came to an end yesterday and for anyone interested in obesity, it has given us a lot to absorb. After four days with a steady stream of new information about drugs like the GLP-1 agonists that regulate appetite and adiposity, we are left wondering. […]
June 24, 2024 — One thing is plain to us in the huge showing of interest in obesity at the American Diabetes Association Scientific Sessions (ADA2024). The scale of opportunity is large because the unmet medical need is great. And yet we face a tremendous problem of scale for coping with the need for obesity care. We have problems […]
June 22, 2024 — We like to celebrate firsts. And yesterday, we got one to celebrate in the first ever drug treatment shown to be effective for sleep apnea – the obesity medicine called tirzepatide. In presenting this new research at the American Diabetes Association Scientific Sessions yesterday, Atul Malhotra reminded us, “sleep is an important part of cardiometabolic […]
June 20, 2024 — It’s quite weird, actually, watching the contortions of health plans as they twist to resist the rising tide of obesity medicines. Because despite the twisting and contortions, obesity medicines are as difficult to resist as a rising tide. Those who pretend it is not happening find themselves under water. A new survey from the International […]
